Integer Holdings Corporation
ITGR Healthcare Medical Devices
Integer Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 7.98% from fiscal 2024. In the quarter to June 2026, revenue fell 2.60%, EPS fell 34.9%, free cash flow grew 48.8% and total debt rose 4.96%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow ITGR
Integer Holdings Corporation (ITGR) EV/Sales
As of 16 October 2026, Integer Holdings Corporation (ITGR) trades at a EV/Sales of 3.0×. Over the past ten years it has ranged from 1.7× (October 2016) to 3.8× (September 2018); the current reading is higher than 73% of that period. That is above the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.1× | (33.01%) |
| FY2024 | 3.2× | 16.13% |
| FY2023 | 2.7× | 13.93% |
| FY2022 | 2.4× | (19.97%) |
| FY2021 | 3.0× | (4.40%) |
| FY2020 | 3.1× | 14.58% |
| FY2019 | 2.7× | (1.27%) |
| FY2018 | 2.8× | 4.52% |
| FY2017 | 2.6× | 9.66% |
| FY2016 | 2.4× | (33.44%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.4× | 3.79% |
| Mar 2026 | 2.3× | 9.86% |
| Dec 2025 | 2.1× | (19.06%) |
| Sep 2025 | 2.6× | (14.93%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LIVN LivaNova PLC compare | 2.7× |
| BRKR Bruker Corporation compare | 2.9× |
| ITGR Integer Holdings Corporation | 3.0× |
| NEOG Neogen Corporation compare | 3.6× |
| UFPT UFP Technologies, Inc. compare | 3.8× |
| TMDX TransMedics Group, Inc. compare | 4.2× |
| IRTC iRhythm Holdings, Inc. compare | 4.4× |
| HAE Haemonetics Corporation compare | 4.7× |
| BFLY Butterfly Network, Inc. compare | 16.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)